Catalog No.
PHE60801
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human IDH2 (Ala40-Gln452).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Isocitrate dehydrogenase [NADP],mitochondrial,IDH2,IDH,ICD-M,NADP(+)-specific ICDH,IDP,Oxalosuccinate decarboxylase
Purification
Purified by antigen affinity column.
Accession
P48735
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Succinate Accumulation Accelerates Oxidative Stress to Promote Pulmonary Epithelial Cell Apoptosis During Lung Ischemia-Reperfusion Injury., PMID:40484976
Biological and Clinical Relevance of Genetic Alterations in Peripheral T-cell Lymphomas., PMID:40416001
The roles of IDH2 and glutathione metabolism in cetuximab resistance in head and neck squamous cell carcinoma investigated by metabolomics and transcriptomics., PMID:39842530
Single-cell mapping of regulatory DNA:Protein interactions., PMID:39803441
MYB::QKI fusion-positive diffuse glioma of the cerebellum: A case report., PMID:39569742
Current status and research directions in acute myeloid leukemia., PMID:39300079
A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL., PMID:38983865
The Role of Novel Immunohistochemical Markers for Special Types of Breast Carcinoma., PMID:37746900
Targeting PRMT1 prevents acute and chronic graft-versus-host disease., PMID:37735873
Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review., PMID:37551557
The Contribution of Multiplexing Single Cell RNA Sequencing in Acute Myeloid Leukemia., PMID:37489448
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma., PMID:37265425
[Novel Strategies to Treat Acute Myeloid Leukemia]., PMID:36990117
TERT Immunohistochemistry as a Surrogate Marker for TERT Promoter Mutations in Infiltrating Gliomas., PMID:36952585
Pathologic and molecular insights in nodal T-follicular helper cell lymphomas., PMID:36793612
Resistance to targeted therapies in acute myeloid leukemia., PMID:36318439
The Diagnostic Utility of IDH2 R172 Immunohistochemistry in Tall Cell Carcinoma With Reversed Polarity of the Breast., PMID:36222504
Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality., PMID:35625998
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma., PMID:35606087
IDH1/2 Mutations in Sinonasal Undifferentiated Carcinomas : Previously Undescribed IDH2 R172K and R140x Variants., PMID:35486703
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic., PMID:35318270
IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis., PMID:35262523
Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia., PMID:35216478
What to use to treat AML: the role of emerging therapies., PMID:34889359
Clinicopathologic Features and Prognosis of Olfactory Neuroblastoma with Isocitrate Dehydrogenase 2 Mutations., PMID:34856401
Harnessing the benefits of available targeted therapies in acute myeloid leukaemia., PMID:34687602
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens., PMID:34489470
Treatment for Relapsed/Refractory Acute Myeloid Leukemia., PMID:34095756
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting., PMID:33879198
Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2., PMID:33801781
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial., PMID:33765335
Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite Lymphoma Potentially Mimicking Richter Syndrome., PMID:33739791
Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia., PMID:33577442
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma., PMID:33496747
IDH mutations in older patients with diffuse astrocytic gliomas., PMID:33137656
Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants., PMID:33017591
The Time Has Come for Targeted Therapies for AML: Lights and Shadows., PMID:32700072
Treatment of Relapsed Acute Myeloid Leukemia., PMID:32601974
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma., PMID:32293336
Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells., PMID:32245484
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity., PMID:31896809
Sinonasal Undifferentiated Carcinoma (SNUC): From an Entity to Morphologic Pattern and Back Again-A Historical Perspective., PMID:31876536
Single-agent and combination biologics in acute myeloid leukemia., PMID:31808888
Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?, PMID:31779969
[What is recommended in the treatment of acute myeloid leukemia?]., PMID:31690995
IDH-1 polymorphisms in pilocytic astrocytomas., PMID:31677487
[Current standard in diagnostic and therapy of peripheral T-cell lymphoma]., PMID:31594013
How we manage adults with myelodysplastic syndrome., PMID:31568568
Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9., PMID:31412117
Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients., PMID:31240524
For research use only. Not for human or drug use.
